logo-loader
viewAvita Medical Ltd

Avita Medical receives regulatory update

au_medical_chart350_54163c21841ce.jpg

Regenerative medicine company Avita Medical (ASX:AVH) has been granted a trading halt this morning with its shares placed in pre-open.

Avita requested the halt after it received a regulatory update.

Avita develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects.

The company’s patented and proprietary tissue‐culture, collection and application technology provides treatment solutions derived from a patient’s own skin.

The halt will remain in place until the opening of trade on Wednesday 17th September 2014, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Avita Medical Ltd

Price: 0.6975 AUD

ASX:AVH
Market: ASX
Market Cap: $621.49 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Collagen Solutions released financial number showing more...

Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.  Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.

7 hours, 5 minutes ago

2 min read